MEDAL – Hepatiske sikkerhedsresultater Etoricoxib var associeret med signifikant lavere hyppighed af seponering på grund af leverrelaterede hændelser end diclofenac.
Etoricoxib was associated with a statistically significantly lower rate of discontinuations due to hepatic- related adverse experiences than diclofenac.